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Elephant in the Dark 
 
Some Hindus have an elephant to show. 
No one here has ever seen an elephant. 
They bring it at night to a dark room. 
 
One by one, we go in the dark and come out 
saying how we experience the animal. 
One of us happens to touch the trunk. 
“A water-pipe kind of creature.” 
 
Another, the ear. “A very strong, always moving 
back and forth, fan-animal.” 
Another, the leg. “I find it still, 
like a column on a temple.” 
Another touches the curved back. 
“A leathery throne.” 
 
Another, the cleverest, feels the tusk. 
“A rounded sword made of porcelain.” 
He’s proud of his description. 
Each of us touches one place 
and understands the whole in that way. 
The palm and the fingers feeling in the dark are 
how the senses explore the reality of the elephant. 
 
If each of us held a candle there, 
and if we went in together, 
we could see it. 
(Rumi, 13th century Iran) 
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Scientific environment  
This PhD project has been performed at the Department of Clinical Science at the 
University of Bergen, the Department of Obstetrics and Gynecology at Haukeland 
University Hospital in Bergen. Professor Line Bjørge has been my main supervisor 
and Professor Ole-Erik Iversen has been my co-supervisor. 
Professor Line Bjørge, Medical Director of the Gynaecologic Cancer Unit at the 
Department of Obstetrics and Gynaecology at Haukeland University Hospital in 
Bergen, has experience with management of translational research projects focusing 
on both targeted therapy and genetic profiling of multicomplex disorders. She is also 
part of the Bergen Gynaecologic Cancer Research Group at the University of Bergen, 
which for several years has created a solid foundation in Bergen for translational 
research of gynaecological cancer. 
Professor Ole-Erik Iversen, senior consultant at the Department of Obsetrics and 
Gynaecology at Haukeland University Hospital in Bergen and Department of Clinical 
Science at the University of Bergen, has through the last decade build up a large 
research portfolio on epidemiology of HPV infection and established a separate 
research unit for clinical HPV vaccine trials.  
The project has been cooperation between Line Bjørge, Ole-Erik Iversen and Mette 
Løkeland. Introduction of medical abortion to new countries after 1990 was politically 
obstructed in spite of the obvious medical benefits and demands from women. In 
Bergen, Line Bjørge and Ole Erik Iversen formed parts of the team implementing 
medical abortion in Norway in 1998. The treatment was first offered to women 
pregnant in early first trimester and was a stepwise introduction under close clinical 
and scientific surveillance.  In 2004 Mette Løkeland was included in the team. She has 
been the national promoter for realizing late first trimester medical abortions and home 
administration of misoprostol. As the treatment protocols were introduced to more 
clinics in Norway the percentage of all abortions performed medically increased. 
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Motivated by an interest in understanding the changing national trends in abortion 
treatment, the hospital surveys and registry study were planned and conducted. 
The main funding source has been the Department of Clinical Science at the 
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Background. Medical abortion is a secure way of terminating a pregnancy. Since 
1998, medical abortion with mifepristone and misoprostol has been available in 
Norway. During the last 16 years, the accessibility and use have increased and the 
treatment protocols have both been simplified and designed for different stages of 
gestation.  
Main objectives. In this project we aimed to describe the implementation process of 
medical abortion and different treatment protocols in Norway during the period 1998 
to 2013. Another goal was to evaluate the possible effects of the introduction on 
availability of abortion, access to it, and characteristics of women requesting abortion 
(Paper I). We introduced two treatment protocols, for home administration of 
misoprostol (Paper II) and late first trimester abortions (Paper III), respectively and 
wanted to evaluate the extent to which they were efficient and acceptable. 
Materials and methods. Information on abortion procedures and year of 
implementation was obtained through questionnaires sent to all Departments of 
Obstetrics and Gynaecology in Norway in 2008 and 2012 (Paper I). To portray traits 
of women undergoing abortion, data from 223,692 women recorded in the Norwegian 
Abortion Registry who requested an abortion between 1998 and 2013 were analysed. 
Women undergoing medical abortion were compared to women performing surgical 
abortion based on characteristics of the study population (Paper I). In an observational 
prospective study, the implementation of home administration of misoprostol was 
evaluated in a cohort of 1,018 women (Paper II). Women received 200 mg 
mifepristone in hospital and self-administered 800 mcg misoprostol vaginally. The 
main outcome measures were success rate, evacuation rate, pain, bleeding, 
acceptability and the influence of travel distance (Paper II). A protocol for late first 
trimester abortions was implemented and evaluated through an observational 
prospective study with a cohort of 254 women. Women with a gestational age of 63–
90 days were included. They received 200 mg mifepristone and were admitted as day 
patients in hospital after 36–48 hours, where they self-administered misoprostol 
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vaginally. Every 3 hours, 400 mcg misoprostol was given orally until termination, with 
a maximum of 5 doses. The main outcome measures were evacuation rate, induction-
to-abortion interval, pain, bleeding, number of misoprostol administrations needed and 
acceptability (Paper III). 
Results. Norwegian hospitals have rapidly introduced new treatment protocols. The 
use of medical abortion increased from 5.9% to 82.1% between 1998 and 2013, and by 
2010, all Departments of Obstetrics and Gynaecology in Norway offered medical 
abortion. Waiting time from registered requests until termination was reduced from 
11.3 days in 1998 to 7.3 days in 2013. More women underwent an abortion at 4–6 
weeks gestation when performing a medical termination (41.6%), compared to 
surgical abortion (16.7%). Compared to women with no previous abortion women 
with repeated abortions had a lower tendency to opt for medical abortion. (Paper I). 
Home administration of misoprostol was found to be an effective and acceptable 
method for abortion up to 63 days of gestation. Travel distance did not influence the 
treatment outcome variables (Paper II). The percentage of hospitals offering home 
administration increased from 23.7% in 2008 to 92.1% in 2012. (Paper I). Medical 
abortion was shown to be an effective method for termination of pregnancy in late first 
trimester, and it was found to be acceptable to Norwegian women (Paper III). We 
found an increased prevalence of hospitals offering this method from 23.7% in 2008 to 
84.4% in 2012 (Paper I). 
Conclusions. Norway has experienced an almost complete change in abortion 
treatment from surgical to predominantly medical between 1998 and 2013. Women 
access abortion at an earlier gestational age with the medical method compared to 
surgical, and waiting time between request and termination has been reduced by 35% 
(Paper I). Knowledge and experience received through the implementations of both 
late first trimester abortions and home use of misoprostol in early first trimester, 
unrestricted by travel distance (Papers II and III), have resulted in the availability of 
expanded treatment portfolios in most hospitals.  
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 What is already known What is added by this study 
Paper 
I 
Through a systematic literature search we 
didn’t find any studies presenting a 
complete national overview comparing 
characteristics of women performing 
medical and surgical abortion. Only one 
prevalence study of abortion protocols to 
all clinics. This study from the Netherlands 
found low uptake of medical abortion and 
few protocols following international 
guidelines. Abortion surveillance data are 
available from some countries, but few of 
them are complete. 
Norway experienced an almost complete 
transformation in abortion treatment after the 
introduction of medical abortion in 1998. In 2013 
82.1% of all abortions were completed medically. 
Women who opt for medical abortion perform their 
abortions significantly earlier in pregnancy than 
women choosing surgical abortion. The rate of 
abortions performed within 9 weeks gestation has 
increased from 44% in 1998 to 77.8% in 2013. 
Waiting time has dropped from 11.3 days in 1998 to 
7.3 days in 2013. Norwegian hospitals offer 




Home administration of misoprostol is 
acceptable to women and is equally 
efficient as hospital treatment. Many 
studies include travel limitations. 
Efficacy of home administration of misoprostol was 
found to be identical to hospital treatment. High 
acceptability was confirmed by 95.1% of the 
women being content with home administration and 
this treatment option becoming the preferred 




A limited number of studies have been 
published on women performing abortion 
in late first trimester with mifepristone and 
misoprostol. Complete abortion rate is 
approximately 95% and acceptability is 
high. Number of misoprostol needed and 
induction-to-abortion time increase with 
gestation. 
Late first trimester abortion was implemented as a 
treatment alternative. The rate of complete 
abortions in our study was 91.7%. Neither the 
number of misoprostol administrations needed nor 
induction-to-abortion time were dependent on 
gestational age. Serum-hCG can be used together 




“Why extremists always focus on women remains a mystery to me. But they all seem to. It doesn’t matter 
what country they’re in or what religion they claim. They all want to control women,” (Hillary Clinton, 
World Summit, New York 2012) 
Termination of pregnancy is a frequently used procedure within the field of reproductive 
health. Despite this no other medical practice has the same political potency and is as 
controversial as abortion (1). Even though it is a minor procedure, it is one of the most 
frequent causes of maternal mortality and morbidity in the world (2). This is due to 
unsafe abortions in illegal settings, where access is restrictive or the health services are 
poor, concerning equipment, health personnel and knowledge (3, 4). This again results in 
unsafe abortion being a neglected global public health challenge mainly affecting women 
in the developing world (4). To diminish access to abortions, further restrictions like 
mandatory counselling, waiting time; who can offer abortion and where and when, have 
been introduced in the developed world (5). Deaths caused by unsafe abortion have been 
reduced from 69,000 in 1990 to 47,000 in 2008. This reduction is due in part to a 
replacement of unsafe surgical methods with medical abortion for illegal abortions 
particularly in Latin America and the Caribbean (2). World Health Organization (WHO) 
recommends abortion to be made available at the lowest appropriate level possible within 
the health system (6). Studies have shown that both manual vacuum aspiration and 
medical abortion are equally efficient and acceptable provided by mid-level health 
providers as well as by doctors up to nine weeks gestation (7–9). Surgical abortion 
requires more training and knowledge by health personnel to be safe and efficient (10). It 
is necessary for any abortion service to have access to and knowledge of surgical 
procedures in case of incomplete abortions, but at the same time, increased knowledge 
about and access to mifepristone and misoprostol could help further reduce maternal 
mortality. In places where the number of health providers is low, medical abortion could 
improve access to abortion. The process of scaling up access to abortion after 
liberalization of the abortion law in 2002 in Nepal is an important model for other 
developing countries that want to increase availability (11). The difficult landscape in 
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many remote and rural areas, and a lack of providers to perform safe surgery, limited 
access, and the Nepalese Government therefore decided to include medical abortion in 
the treatment portfolio (11).  
The combination of mifepristone and misoprostol for medical abortion has been available 
since 1988. The use and efficacy for this combination treatment is thoroughly 
documented for use up to nine weeks gestation (12). Mifepristone and misoprostol have 
been made available in a growing number of countries since 1988 (Figure 1). The 
procedure has also been modified and introduced for both late first trimester and second 
trimester abortion (13–15). In 2005, WHO placed the combination of mifepristone and 
misoprostol for termination of pregnancy on its list of essential drugs (16). 
 
1.1 International history of medical abortion 
Mifepristone (RU-486) is an antiprogesteron and antiglucocorticosteroid (17) that was 
developed by Étienne-Émile Baulieu and other scientists while working for the French 
company Roussel-Uclaf in the early 1980s (18). It showed remarkable effect as an 
abortifacient and was introduced to the French market for that indication in 1988 (18). 
Due to controversies and pressure on Roussel-Uclaf by antiabortionists, the company 
wanted to withdraw mifepristone from the market. However, Roussel-Uclaf was put 
under pressure by the French government, which demanded that mifepristone was 
made available to women (18). The French government expressed that "RU-486 is 
also the moral property of women" (19). Mifepristone was only registered in a few 
countries until Roussel-Uclaf transferred the patent to the company Exelgyn, founded 
by the former chief executive of Roussel-Uclaf, Edouard Sakiz, in 1997 (20). Exelgyn 
was given the patent rights for use worldwide, except for the USA market, where the 
patent was transferred to The Population Council (19). Exelgyn produces only 
mifepristone and misoprostol and is consequently less vulnerable to sanctions. 
Mifepristone was registered for use in the United Kingdom in 1991 and Sweden in 
1992 (19). In China, mifepristone was approved for medical abortion in 1986. China 
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has manufactured mifepristone without licence from Roussel-Uclaf (21). In 2013 
mifepristone was registered in 60 countries (Figure 1). Though mifepristone-only can 
cause abortion, the efficacy is much lower than when used in combination with a 
prostaglandin analogue, only 60–80%, in comparison to 95% (1) (See also paragraphs 
1.5 and 1.6). Misoprostol as a single drug for termination of pregnancy is used in 
many parts of the world, particularly in illegal settings where mifepristone is not 
registered (1). Efficacy for the misoprostol-only regimen is about 90% (1). 
Recommendations are to use mifepristone with the prostaglandin analogue misoprostol 
(12). 
 
Unfortunately, prenatal exposure to misoprostol, in high dosages, is associated with an 
elevated risk for defined congenital malformations (22). Anomalies have not been 
identified after mifepristone use (23, 24).  
 
 
Figure 1.  Map of mifepristone approvals (www.gynuity.org).  
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1.2 Norwegian history of medical abortion 
Norway has had abortion on request up to 12 weeks gestation, according to the 
Norwegian Abortion Act, since 1979 (25). Abortion is completely free of charge and 
available at every hospital with a Department of Obstetrics and Gynaecology. According 
to the law, only doctors are entitled to perform abortions. The County Governor can 
approve facilities outside of hospital to perform abortions (25). In Norway, the first 
clinical trial with mifepristone was initially planned in 1989 at Ullevål University 
Hospital, Oslo. The Christian Democratic Party filed a proposal in Parliament to ban 
mifepristone from the Norwegian market. Before Parliament managed to deal with the 
“mifepristone case”, Roussel-Uclaf withdrew their suggested registration of mifepristone 
in Norway. Parliament for its part saw no reason not to allow the use (26). Although 
gynaecologists and the medical profession in general have been positive to the 
introduction and use of mifepristone, it has taken time to increase the accessibility. The 
European Economic Area (EEA) agreement that facilitated the access to drugs available 
in other EEA countries was put into action in 1994. Together with the establishment of 
Exelgyn in 1997, this enabled the introduction of mifepristone to Norway in 1998. The 
first hospital to introduce the combination of mifepristone and misoprostol for early first 
trimester abortion was Haukeland University Hospital, rapidly followed by two other 
university hospitals within the same year (Paper I). Mifepristone was registered for use in 
Norway in January 2001 (27), and Bjørge et al. published the first experience of medical 
abortion in Norway in 2001 (28). Home administration of misoprostol was introduced at 
the regional hospital in Førde in 2003. Only when the university hospitals Ullevål 
University Hospital and Haukeland University hospital introduced the possibility of 
home administration in 2005 (29) and 2006 (paper II), respectively, focus in the media 
led to a political reaction (30). A proposal to ban home administration of misoprostol, on 
the grounds that women should not be left alone with the possible emotional side effects 
an abortion could have, was made in Parliament by three parliamentarians (31). Their 
proposal was defeated, but resulted in a review made by the Directorate of Health (32). 
This report found home administration to be safe, efficient and preferred by many 
women. The conclusion was that the procedure should be offered as an option (32). Until 
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2008 surgical abortion was the most common procedure for terminations of pregnancies. 
Since 2008 the use of medical abortion has rapidly increased to 82.1% of all abortion 
performed medically in 2013 (33, Paper I).  
In 2010 the Government allocated money in the National Budget for a pilot project 
where medical abortion could be offered by gynaecologists in outpatient clinics (34). 
The project started in 2012, run by the Directorate of Health (35), and the treatment 
option will be introduced early 2015. 
 
1.3 Access 
Worldwide access to abortion is dependent on many factors. First of all, safe abortion 
is dependent on national laws, and if these are restrictive, give access according to 
broad medical and social indications, or on request. On the other hand, laws are 
subject to interpretation, and there might be discrepancies between the wordings of the 
laws (de jure) and how they are applied (de facto) (36). Laws and regulations also 
restrict access to abortion through limiting when and where the procedures can be 
performed and by whom. Travel and abortion fees are limiting factors for women with 
few economic resources. Waiting time, mandatory counselling, and the right to 
conscientious objection are other factors that can reduce availability. Several of these 
factors have been affected by the implementation of medical abortion and some have 
been subject to political discussions (31, 37). 
 
1.3.1 When 
The Norwegian Abortion Act is fairly liberal compared to most other national laws. 
Women have the right to abortion on request up to 12 weeks gestation. After 12 
weeks, women need the permission from a commission of two doctors to legalize a 
termination. Abortion is not to be permitted if the foetus is viable, except if the 
woman’s life is at risk (25). A Public Hearing currently ongoing, from the Minister of 
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Health, suggests limiting abortion upwards to 21 weeks and 6 days (38, 39). The 
Norwegian law favours early abortion and is more restrictive to abortions after 12 
weeks gestation. In comparison the Swedish law has abortion on request up to 18 
weeks gestation (40), the English law has an upper limit of 24 weeks (41) and in the 




As mentioned, every hospital with a Department of Obstetrics and Gynaecology 
(Figure 2) are obliged to offer the procedure. Abortion should take place in hospitals, 
but the law includes a possibility for exceptions to the general rule. The County 
Governor can, as already mentioned, give permission for abortion to be carried out in 
other facilities (25). This exception was adopted in 2014 and makes it possible for 
gynaecologists in outpatient clinics to carry out medical abortions (see also paragraph 
1.2) (35). Home administration of misoprostol complies with the law as long as 
mifepristone is taken under observation at the health facility supervising the treatment.   
 
 
Figure 2.  Distribution of hospitals performing abortions in Norway 
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Some politicians have even voiced the possibility of abortion being performed by 
general practitioners (GP) (43). That would increase accessibility even further, and be 
in line with WHO recommendations that abortion should be available at the lowest 
appropriate level possible (6). Figure 3 illustrates three different scenarios for access to 
medical abortion in the Norwegian region Finnmark. 
 
 
Figure 3.  Three scenarios for distribution of abortion treatment in Finnmark, 
Norway. 1. Hospital (current situation 2014) (red dot), 2. 
Gynaecologists (yellow dot), 3. General practitioners/primary health 
care (red box) 
 
1.3.3 Who 
Only physicians are entitled to perform abortions according to the law, but the law 
does not prohibit delegation under supervision to other health professionals. 
Throughout the country, nurses have an increasingly important role in abortion 
treatment. In many hospitals they do counselling, hand out medication, care for 
women having the treatment in hospital and do telephone interviews for check-ups and 
controls. Medical doctors have commonly conducted the ultrasound for pregnancy 
confirmation and the determination of gestational length, and they prescribe the 
medication or perform the surgical abortion. A similar development in the abortion 
services has also been seen in Sweden (9).  
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1.3.4 Cost, counselling, conscientious objection and waiting time 
A service free of charge is one of the most important factors to secure access to 
abortion. In Norway emergency treatment is available free of charge for everybody 
independent of legal citizenship status. Abortion is defined as an emergency treatment 
and as a consequence abortion is free of charge for everybody (44). Travel expenses 
are also refunded (45).  
Counselling is not mandatory in Norway as in for example some other countries in 
Europe (46) and some states in the USA (47), but should be offered to all women as an 
option (25).  
Health personnel in Norway have the right to conscientious objection in the case of 
performing or assisting during a surgical abortion or to prescribe and/or hand out the 
medication for medical abortion. The right to conscientious objection does not cover 
handling women who request an abortion, refusing to refer them or not performing an 
emergency surgical evacuation (25, 48). A public hospital is obliged to offer abortion 
services to women who request them and cannot claim a right to conscientious 
objection (25). These obligations stand in contrast to many other countries, where 
women’s access is dependent on women finding a clinic or physician who is willing to 
perform an abortion (49). Norway witnessed a huge public debate in 2013–2014 after 
a proposal was raised by the Minster of Health to grant GP’s the right to perform their 
conscientious objection according to the European Parliament Resolution 1763 (2010). 
After pressure and a public mass movement, the Minister of Health withdrew his 
proposition (37).  
In some parts of the world waiting time is mandatory (46). There is no mandatory 
waiting time in Norway and women do not need a referral to access abortion. They can 
contact a hospital directly themselves. Even when there is no obligatory waiting time, 
women can still experience some delay. Waiting time between the making of a request 
for an abortion and when it is executed is highly dependent on logistics at hospital 
level (50, 51). Flow charts organizing and scheduling treatment determine when 
women are scheduled for a visit, the timing between first visit and abortion procedure, 
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and number of visits needed (Figure 3) (50, 51). Women prefer one single visit (51). 
The introduction of home administration of misoprostol has made it possible to reduce 
the number of visits.  
 
 
Figure 4.  Number of visits to have an abortion with different protocols 
 
1.4 Choice 
Today a more informative model has replaced a paternalistic doctor-patient 
relationship. Patient autonomy equals the right to information and choice based on 
personal preference and has in some ways placed patients in the role of consumers (52, 
53). The right to a choice is presented as an undivided positive opportunity and 
necessity (54). In psychological research on consumerism, one finds that people 
routinely violate so-called rational choices (55). To choose is not always easy. You 
might not always know if you made the right choice and if you regret your choice you 
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only have yourself to blame (55). Different personalities behave differently when it 
comes to choice and research has demonstrated that people who are more arbitrary 
towards choice and are happy with “good enough” the so called “satisficers” are 
happier than those who always want “the best”, the “maximizers” (55).  
Knowledge about the importance of choice of abortion methods or other health 
treatments is low compared to studies on consumerism. A study from the United 
Kingdom (UK) in 1993 found that 54% had no preference and were willing to be 
randomised between surgical and medical abortion (56). Acceptability was high in all 
treatment groups, but slightly higher among women who were not randomised (56), 
and this was confirmed in a two-year follow-up study of the same population (57). 
They maintained a higher preference for vacuum aspiration and 69% rated the 
possibility of choice as very important (57). In comparison, the first study on medical 
abortion from Norway found that 69% of the women who opted for medical abortion 
and agreed to participate in the study were not willing to be randomised (28).  
The question of choice probably holds a particularly strong importance regarding 
every aspect of abortion and abortion methods due to controversies surrounding 
abortion and its political arguments based on “pro-choice” (54). The question of 
maternal request for caesarean sections (CS) is an increasingly controversial issue that 
could be comparable to choice of abortion method (53). In a study from the UK 
following pregnant women and their preferred mode of delivery, the study found that 
even though most women supported the right to choose, they were uncomfortable with 
making the choice themselves. Women felt that health concerns were more important 
than choice, and that health professionals should have the final say providing the best 
health option. This tendency increased as the pregnancy developed (53).  
A general principle is to use a less or non-invasive procedure if the conservative 
treatment is equally effective and acceptable or more than surgery. Minimal invasive 
procedures replace surgery to improve patient safety in many fields of medicine. After 
a time of building experience and skills, the new, less invasive and more cost-efficient 
procedure replaces the former procedures without question of patient choice. Many 
 24
Norwegian hospitals have decided that their method of preference is medical abortion 
independent of gestational age. This does not eliminate the access to surgical abortion, 
but women have to make an active request to obtain vacuum aspiration. This treatment 
practice has also been defended by the Norwegian Minister of Health (58). 
Accumulating knowledge is a dynamic process. Opinion is modulated by information 
and experience and it is not always easy to define a preference. Most women also 
realize that health personnel are the experts in their field and want their guidance. At 
the same time as we recognize and respect individual preferences and interests, we 
have to evaluate if decision-making as we are used to think of it in consumerism is 
valid in a health setting.  
 
1.5 Dosage of mifepristone 
The first report on mifepristone as an abortifacient was published in 1982 (59). Initial 
studies administered mifepristone alone in repeated doses of 10–150 mg twice a day 
over a period of four to seven days (59-61). With an efficacy of 60–80% it did not 
offer a real alternative to prostaglandin only or vacuum aspiration (59, 62) until studies 
combining mifepristone in a single dose and a prostaglandin analogue revealed an 
efficacy of about 95% (59, 63). These results provided the basis for a protocol 
consisting of 600 mg mifepristone combined with a prostaglandin analogue (1, 59) 
(See also paragraph 1.2). The first Norwegian treatment protocol introduced in 1998 
consisted of 600 mg mifepristone in combination with 800 mcg misoprostol vaginally 
(28). Since the early start of medical abortion, research has been performed to find the 
minimal effective dose of mifepristone and the most appropriate dose, type and 
administration form of prostaglandins to minimize side effects. A WHO randomised 
controlled trial found 200 mg mifepristone to be equally effective as 600 mg when 
combined with a prostaglandin (64), while a reduction to 50 mg mifepristone resulted 
in lower efficacy and was not recommended (65). Lowering the dose of mifepristone 
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to 100 mg was found to be promising in a WHO randomised equivalence trial (66). 
The recommendation in Norway is 200 mg mifepristone for all gestations (67, 68).  
 
1.6 Administration of misoprostol 
In the early protocols for medical abortion, mifepristone was commonly used together 
with the prostaglandin analogues gemeprost and misoprostol. Gemeprost was used 
through the vaginal route, and misoprostol orally. Gemeprost was registered for use up 
to 63 days gestation in Sweden and the UK and misoprostol was registered up to 49 
days gestation in France and the USA (1). Misoprostol has reduced effect after 49 days 
gestation when used orally (1). Gemeprost is more expensive and unstable at room 
temperature in comparison to misoprostol and therefore less useful in all settings and 
particularly in the developing world. This has led to research establishing 
administration protocols for misoprostol with equal efficacy to gemeprost (69, 70). El 
Rafaey et al. identified as early as in 1995 that vaginal administration of 800 mcg 
misoprostol had higher efficacy and fewer side effects than 800 mcg misoprostol 
orally (Table 1) (70).  
 
 Mifepristone 600 mg  Mifepristone 200 mg  









Complete abortion 113 (87) 126 (95) 436 (96.2) 451 (98.7) 
Incomplete  8 (6) 6 (4) 9 (2.0) 5 (1.1) 
Ongoing pregnancy 9 (7) 1 (1) 8 (1.8) 1 (0.2) 
Table 1.  Mifepristone with oral or vaginal misoprostol and mifepristone with vaginal   
gemeprost or misoprostol (69,70) 
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With increasing gestational age, higher total doses of misoprostol are needed. 
Treatment protocols for late first trimester abortions and second trimester abortions 
include additional doses of misoprostol (13-15). A lower success rate for abortions 
after 56 days gestation is also observed and has prompted the addition of 400 mcg 
misoprostol offered for abortions up to 63 days gestation that have not been expulsed 
within four hours (71-73). 
Common side effects of prostaglandins are mainly gastrointestinal like nausea and 
diarrhoea (12, 62, 69, 70). A number of studies have experimented with different 
routes of administration to reduce unwanted side effects, increase success rate and 
improve acceptability (12, 62).  
Pharmacokinetic studies have found a rapid increase in serum concentration after 
sublingual and oral administration and a more prolonged increase after vaginal use, 
while sublingual and vaginal use maintains a higher concentration after two hours. 
This correlated with higher uterine contractility after two hours following sublingual 
and vaginal use and more side effects after oral and sublingual administration (74, 75). 
Although buccal and sublingual administrations show similar success rates to vaginal 
use, the number of side effects is less for the vaginal administration route. (12, 62). In 
the revised Norwegian national guidelines, vaginal administration will be 
recommended with buccal use as an alternative to oral administration for repeat 
dosages of misoprostol (67). 
To improve flexibility for women requesting abortion different intervals of 0–72 hours 
between mifepristone and misoprostol have been analysed (71, 76). Even though it is 
shown that maximum contractility is achieved 36–48 hours after mifepristone intake 
(77), several studies find no statistically significant difference in efficacy when 
misoprostol is administered at shorter intervals (71, 76). There seem to be some limits 
though. In the review by Wedsinghe et al. (76), efficacy for the treatment was lower 
when the intervals between mifepristone and misoprostol became shorter than eight 
hours and in a review by Raymond et al. they found reduced efficacy when the interval 
was shorter than 24 hours (71). 
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1.7 Follow-up protocols  
Control procedures have seldom, if ever, been included in surgical abortion protocols. 
Robust systems for follow-up to identify failures have on the other hand been included 
in medical method protocols (78). Depending on the protocol used and gestational age, 
the failure rate is described to be in the range of 0.3%–3% (72, 78, 79). The low 
incidence rates make it difficult to evaluate the different follow-up procedures (78). 
Routine follow-up after a medical abortion included initially a clinical exam with or 
without vaginal ultrasound examination (78) and this has later often been referred to as 
“the golden standard”. The use of ultrasound and extra visits is neither cost- and time-
efficient to the women nor to the health personnel (78). Therefore to increase access 
and simplify the medical abortion protocols in use, several other options for follow-up 
have been introduced and evaluated (78).  
Although studies have found that women are fairly accurate at determining themselves 
whether the abortion has been successful or not (78, 80, 81), the accuracy is too low 
for self-assessment to be recommended as the only method. Use of s-hCG has the least 
false negatives. Commonly s-hCG levels at the time of mifepristone intake would be 
compared with s-hCG 6–28 days later as a reference for control (14, 82, 83). A decline 
in s-hCG of more than 80% or below a cut of value could be used as a marker of 
success (14, 82, 83). A drawback with this form of follow-up is the need for additional 
visits. Urine pregnancy tests (UPT) are becoming increasingly popular (Paper I). 
Women prefer the option of self-assessment with UPT to clinical exam (79). 
Unfortunately there is a risk of false negatives following the use of UPT (78, 79). 
Studies on the use of a combination of high and low sensitive u-hCG tests, self-
assessment and telephone interviews show promising results (79, 84). Haukeland 
University Hospital has introduced a three step follow-up protocol starting with a high 
sensitive (HS) UPT (Figure 5).  
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Figure 5.  Follow-up protocol at Haukeland University Hospital 
 
Endometrial thickness is not a good marker for surgical intervention following medical 
abortion (14, 82, 83), and several studies indicate that the rate of surgical evacuation is 
reduced with accumulated experience (1). A further reduction of unnecessary surgical 
interventions might be accomplished if ultrasound examination is left out of follow-up 
protocols (14, 64, 82, 83).  
 
1.8 Home administration of misoprostol 
Home administration of misoprostol is the most common procedure for medical 
abortion up to nine weeks gestation in the USA (85). In Europe the story has been 
slightly different. Except for Scandinavia, the access to home administration of 
misoprostol has been more restricted. Restrictions upward to a gestational age of 49 
days, limitations on travelling time from the provider or complete prohibition of home 
administration reduce access (72, 86, 87). As many women prefer one single visit (51), 
the use of home administration for abortions at higher gestational ages has also been 
suggested. Recent publications have shown this to be an acceptable and efficient 
alternative up to 70 days gestation (88, 89). One study has also found home 
administration up to 12 weeks gestation to be tolerable (90).  
HS-UPT 
after 4 weeks 
Positive 
s-hCG at GP 
>500  
Ultrasound 




Negative Abortion complete 
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1.9 Late first trimester medical abortions 
Medical abortion for use up to nine weeks is well-documented through multiple 
studies including two Cochrane reviews (12). Already in 1998 Ashok et al. published a 
study of 298 women with a gestational age 9–13 undergoing medical abortion (91). 
Even though the study showed satisfactory results in line with results for medical 
abortion up to nine weeks gestation, medical abortion for this gestational age has not 
reached the same common use for termination of pregnancy. Through systematic 
literature search using the keywords mifepristone, misoprostol, medical abortion, 9–
13, 9–12, 63–84, 63–90 and 63–91, we have been able to identify 14 studies on late 
first trimester abortions (Table 2). The research group in Aberdeen has authored six of 
them.  
It has previously been found, as mentioned, that 200 mg mifepristone shows equal 
efficacy as 600 mg for medical abortion up to nine weeks gestation (12). In 12 out of 
14 studies, women received 200 mg mifepristone with success rates equal to the study 
using 600 mg mifepristone, and similar to those documented in early first trimester 
abortions (12). One study used 200 mg mifepristone followed by repeat doses of 
gemeprost vaginally (92). The results of that regimen were equal to the combination of 
mifepristone followed by 800 mcg misoprostol vaginally and repeat doses of 400 mcg 
misoprostol until completion, which was used in 11/14 studies.  
One study randomised between 200 mg mifepristone followed by either 800 mcg 
misoprostol vaginally or 600 mcg sublingually, and repeat doses of misoprostol if 
necessary. They found equal efficacy and acceptability between the two methods but 
more side effects of nausea and diarrhoea with the sublingual group (93). The two 
studies with misoprostol only (90, 94), and the combination of 200 mg mifepristone 
followed by 400 mcg misoprostol orally (90), had a lower success rate than the other 
studies.   
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Treatment protocol Success rate 




1998 120 9–13 weeks 200mg mifepristone + 
800 mcg misoprostol 
(36-48 h, vaginal), 
repeat misoprostol 400 
mcg 
95% 
Gouk et al. (95) Middlesbr
ough, UK 
1999 253 63–83 days 200mg mifepristone + 
800 mcg misoprostol 
(36-48 h, vaginal) 
94.5% 




2001 150 9–12 weeks 800 mcg misoprostol 
vaginally     (+ max 






2002 25 9–12 weeks Mifepristone + 
gemeprost (48 h, vag) 
max 5 doses gemeprost 
96% 




2002 486 10–13 weeks 200mg mifepristone + 
800 mcg misoprostol 
(36-48 h, vaginal) repeat 
400 mcg misoprostol. 
Randomised between 








2003 483 64–91 days 200mg mifepristone + 
800 mcg misoprostol 
(36-48 h, vaginal) 
Repeat 400 mcg 
misoprostol 
94.8% 




2003 415 63–84 days 200mg mifepristone + 
800 mcg misoprostol 
(48 h, vaginal).   Repeat 
400 mcg misoprostol 
96% 






2004 105 9–14 weeks 600mg mifepristone + 
800 mcg misoprostol 
(48-72 h, vaginal).  
Repeat misoprostol 
92.4% 




2005 1076 9–13 weeks 200mg mifepristone + 
800 mcg misoprostol 
(36-48 h, vaginal) 









2005 340 9–13 weeks 200mg mifepristone + 
800 mcg misoprostol 
(36-48 h, vaginal) or 
600 mcg misoprostol 
(36-48 h, sublingually). 
Repeat 400 mcg 








2005 368 10–13 weeks 200mg mifepristone + 
800 mcg misoprostol 
(36-48 h, vaginal).  











2007 321 64–84 days 200mg mifepristone + 
800 mcg misoprostol 
(24-48 h, vaginal).  
Repeat 400 mcg 
misporsostol 
89% 




2010 122 9–12 weeks 1. 200mg mifepristone + 
400 mcg misoprostol 
(48h, oral)  + 400 mcg 
misoprostol.                       
2. 800 mcg misoprostol 
(vaginal) + 400 mcg 
misprostol 
80.8% 
              
77.4% 




2010 254 63–90 days 200mg mifepristone + 
800mcg misoprostol 
(36-48h, vaginal). 




Table 2. Studies on late first trimester abortions presented with author, place, year, 
population, gestational age, treatment protocol and success rate 
 
Seven of the studies focusing on efficacy of the method also include measures of 
acceptability (acceptability of side effects, preference for future method and 
recommendation to others) (14, 90, 91, 93, 100, 101). They all found a high rate of 
acceptability, and all studies conclude that medical abortion in late first trimester 
should be offered as an option to women. The group from Aberdeen has also published 
a partially randomised patient preference study comparing medical and surgical 
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abortion at 10–13 weeks gestation. In this study the majority of the women would 
choose the same procedure for a new abortion if needed, and the preference was higher 
if they had a prior preference for the actual procedure before having the abortion 
(100).  
 
1.10 The professional environment 
The Norwegian professional environment of obstetricians and gynaecologists is relatively 
small, which facilitates transparency and the exchange of new knowledge and experience. 
The annual meeting of the Norwegian Society of Obstetrics and Gynaecology (NSOG) 
serves as an important conference for medical discussion and presentation of new 
research and is together with the biannual Nordic Congress of Obstetrics and 
Gynaecology the most frequently visited. 
NSOG was the first medical society in Norway to publish national guidelines (in 1995 
(Obstetric) and 1996 (Gynaecology)). The second guidelines were published in 2004 and 
included medical abortion. The recommended treatment protocol was in 2004 200–600 
mg mifepristone, admission to hospital and administration of 800 mcg misoprostol 
vaginally after 42–48 hours, up to nine weeks gestation (102). In the current guidelines 
from 2009 the recommended protocol is 200–600 mg mifepristone, self-administration of 
800 mcg misoprostol vaginally after 42–48 hours, either at home or in hospital, up to 
nine weeks gestation and 200 mg mifepristone, admission to hospital after 42–48 hours 
and the administration of 800 mcg misoprostol followed by up to five repeat doses of 400 
mcg misoprostol until termination (68).  
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2. Aims of the thesis 
Pregnancies can be terminated safely by medical abortion at any stage of gestation (1, 
103). Medical abortion with mifepristone and misoprostol has been available in Norway 
since 1998. During the last 16 years the availability and use have increased and the 
treatment protocols have both been simplified and designed for different stages of 
gestation. Increased availability and knowledge about medical abortion have resulted in 
simplified regimens. Subsequently the establishment of different therapeutic modalities 
has facilitated the possibility of offering more individualized treatment to Norwegian 
women for termination of pregnancy.  
Norway is one of few countries in the world with a full national registration of all 
abortions conducted. Through the Abortion Registry, the possibility exists to examine 
possible effects the change in abortion practice, from predominantly surgical to largely 
medical abortions, might have had on access to abortion and on socioeconomic 
determinants in the abortion population.  
The specific aims were: 
1. To describe the implementation process and possible effects the introduction of 
medical abortion to Norway in 1998 to 2013 has had on access and current 
medical abortion practice, and to compare characteristics of women according to 
abortion method used (Paper I). 
2. To implement and evaluate the efficacy and acceptability of medical abortion with 
home administration of misoprostol up to 63 days gestation (Paper II). 
3. To implement and evaluate the efficacy and acceptability of medical abortion at 
63 to 90 days gestation (Paper III). 
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3. Material and methods 
3.1 Data resources and study populations 
3.1.1 Hospital surveys (Paper I) 
A questionnaire was sent to all hospitals performing abortion in 2008 and 2012 
(Appendix 1). Names, addresses and number of hospitals were found using 
Helseadresser.no, a web page delivered by the Norwegian Directorate of Health 
(Appendix 2). There was a reduction from the original list of 40 hospitals in 2008 to 
38 in 2012 due to reallocation of services. The Abortion Registry in its annual report 
names 34 hospitals and reports receiving data from 44 different providers (33). The 
discrepancies between the list of hospitals and the number of providers in the 
Registry’s annual report are due to some divisions within the same hospital reporting 
separately to the Abortion Registry (33). Some formerly independent hospitals have 
also been reallocated on an administrational level between 1998 and 2013 to a larger 
hospital, while maintaining services. We have chosen to include these formerly 
independent hospitals in our surveys. 
After considering existing national guidelines (102), varieties of treatment protocols 
personally reported to us, and scientific literature, the study group designed the 
questionnaire. Questions related to intervals between intake of mifepristone and 
administration of misoprostol were unfortunately not included. 
Hospitals that did not return the questionnaire received a phone call as a reminder. The 
response rate was 100% for both surveys.  
Some discrepancies were found in the time specified as the first introduction of 
medical abortion in the questionnaires for 2008 and 2012 for some of the departments. 
In these cases we chose to primarily record data from the 2008 questionnaire.  
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3.1.2 Abortion Registry (Paper I) 
Statistics on requests for, and termination of, pregnancy have been available in 
Norway since 1979. Statistics Norway was responsible for collecting and presenting 
these data from 1979–2005 (104). Since 2006, the Norwegian Institute of Public 
Health has been responsible for the statistics, and the institution has handled the data 
processing since 2008 (33). Processing, storage, collection and handling of data in the 
Abortion registry is governed by the Abortion Registry Regulation and the Health 
Registry Act (105). The purpose of the Abortion Registry is to produce statistics to 
monitor how the law on abortion is practiced, evaluate measures initiated to prevent 
unwanted pregnancies and abortion, and contribute to good resource utilisation and 
quality in the treatment of women’s reproductive health (105). The information in the 
Abortion Registry is de-identified. The woman’s name and personal identification 
number and other unique personal identifiers have been removed (105). Data are 
collected at hospital level through a standard form that contains check boxes with 
specific answer alternatives. The standard form has been changed a number of times 
since 1979, and three different forms have been in use between 1998–2013 
(Appendixes 3, 4 and 5). The current form was created in 2006. Data approved by the 
Abortion Registry Regulation for inclusion are: date of birth, county and municipal 
residence, information on contraceptive use, gestational age, parity, number of 
previous abortions, previous medical history, abortion method, complications to the 
procedure; civil, occupational and educational status (105). Due to delay in developing 
the abortion form, registration of medical abortion as a specific method for abortion 
was first included in 2006.  
Parameters from the Abortion Registry used in this study were; year of termination, year 
of birth, age, marital status, employment status, educational level, previous pregnancies, 
number of children, previous terminations, date of registered request for abortion and 
method used (Paper I).   
The Abortion Registry contains data on all requests for an abortion, and some of them 
will not be fulfilled (Appendix 6). Requests that do not end in a termination commonly 
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lack information on most parameters. We analysed data comprising 223,692 terminations 
of pregnancies up to 12 weeks gestation in Norway 1998–2013.  
 
3.1.3 The clinical cohorts (Papers II and III) 
Two clinical cohorts were collected, established and analysed to evaluate the 
implementation of home administration of misoprostol and late first trimester medical 
abortion, respectively. The observational studies took place during the periods May 
2006–May 2009 and October 2005–April 2007, separately. All women who chose to 
receive the treatments in question were registered. In total 1,018 women with a crown-
rump-length (CRL) up to 23 were included in the study on home administration of 
misoprostol and 254 women with a CRL of 23–66 were involved in the late first 
trimester study. Data on parity, previous abortions, age of the woman, gestational age, 
CRL, date of mifepristone and misoprostol intake, s-hCG at mifepristone intake and at 
control, bleeding, pain and acceptability were recorded in both studies (Papers II and 
III). Travel distance and travel time was additionally measured in Paper II, and the 
induction-to-abortion interval, as well as the number of misoprostol administrations, 
was recorded in Paper III. Information in the files was crosschecked with data in the 
electronic patient system to ensure good data quality before storage. The information 
in the files was de-identified, validated and stored at the internal secured site at the 




3.2 Treatment protocols, exposure and outcome variables 
This section provides an overview and explanation of different variables that were 
chosen for the studies. 
 
3.2.1 Paper I 
Mifepristone dosage: According to national guidelines from 2004, recommended 
dosages were 200–600 mg (102). 
Administration of misoprostol: National guidelines for administration of misoprostol 
recommended 800 mcg vaginally (102). Additionally we received reports on oral use 
of misoprostol and oral administration was therefore included as an option in the 
questionnaire. 
Follow-up: Clinical exam with ultrasound was the only recommended protocol in the 
national guidelines from 2004. The use of s-hCG as the only form of follow-up was 
defined as low evidence in the national guidelines from 2004. We received 
information about hospitals using UPT, and follow-up being excluded from other 
hospitals and these options were included in the questionnaire. 
Study period for the thesis: The first treatment with mifepristone and misoprostol was 
conducted in 1998. Data in the Abortion Registry up to 2013 were completed and 
quality controlled by April 2014 and could be included in the study. The two clinical 
cohorts had their own defined study period previously reported in paragraph 3.1.3. 
Waiting time: Waiting time was defined as the mean difference in days between the 
dates a request for abortion was registered by the hospital until termination.  
Gestational age: In the Abortion Registry gestational age is recorded as complete 
weeks and is based on 1. Ultrasound, 2. Clinical exam, 3. Last menstrual period 
(Listed in order of priority). 
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Medical abortion: Medical abortion was included as a specific option in the report 
form to the Abortion registry in 2006. For abortions prior to 2006, medical abortion 
has been defined as “injection of abortifacient” or “local application of prostaglandin” 
and simultaneously absence of surgery. 
Repeat abortion: In Paper I, repeat abortions have been defined as one or more 
previous abortions. Numbers of previous abortions are primarily based on women’s 
self-report. In recent years the use of electronic patient journal systems is increasingly 
prevalent in Norwegian hospitals. Health personnel might be looking to them for 
additional information to improve the quality of data provided to the Abortion 
Registry. Prevention of unwanted pregnancies is one of the main goals of the 
Norwegian government (106). 
Parity: Number of previously born children. 
Educational attainment: Information on educational attainment was first introduced in 
the Abortion Registry in 2006, and is divided into three categories 1. 
Primary/secondary school, 2. High school/upper secondary school, 3. 
College/university. 
Work force attachment: The Abortion Registry contains more subcategories to define 
work force attachment than those we chose for our study (Paper I) (1=full time and 
student, 2=full time, 3=part time and student, 4=part time and social welfare, 5=part 
time and applying for jobs, 6=part time, 7=student, 8=out of work, 9=social welfare). 
To reduce the number of categories we chose to redefine the original categories into 
four. Categories 1 and 2 were recoded into full time, categories 3–6 into part time, 






3.2.2 Papers II and III 
Treatment protocols: The Department of Obstetrics and Gynaecology at Haukeland 
University Hospital has many years’ experience with medical abortion up to 63 days 
gestation. To improve women’s options, a one single visit protocol was introduced for 
home administration of misoprostol. The already established treatment protocol in 
hospital for gestations up to 63 days, consisting of 200 mg mifepristone and 800 mcg 
misoprostol vaginally after 36–48 hours was chosen (Paper II). Treatment protocols 
from previously published studies were chosen and adapted for late first trimester 
abortions (13, 91). All women received 200 mg mifepristone and were admitted as day 
patients 36–48 hours later where they self-administered 800 mcg misoprostol 
vaginally, and a maximum of 5 repeat doses of 400 mcg misoprostol was given orally 
every 3 hours until expulsion.  
Bleeding: Report based on self-assessment in Paper II and nurse evaluation in Paper 
III. 
Pain: Pain was evaluated subjectively by the women (Papers II and III). 
Follow-up in clinical studies: Standard follow-up protocol already in clinical use at the 
Department of Obstetrics and Gynaecology, Haukeland University Hospital, 
consisting of s-hCG after four weeks following mifepristone application was chosen 
for home administration of misoprostol (Paper II). Medical abortion for late first 
trimester abortions was a new treatment option in Norway. Due to no experience with 
medical abortion for this gestational age, a similar implementation protocol as the 
implementation of early medical abortion in 1998 was chosen (28). It consisted of 
ultrasound and clinical exam 1–2 weeks after termination. To evaluate the drop in s-
hCG for this gestational age, a blood test for s-hCG was taken four weeks after 
mifepristone intake (Paper III). 
Travel time: Travel time and distance was measured between the woman’s registered 
address and the hospital’s address using the website “Visveg” 
(http://visveg.vegvesen.no/Visveg/mapviewer.jsf).  
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Acceptability: A set of questions aiming to evaluate acceptability was applied in both 
clinical studies. In Paper II, women were asked during a telephone interview on the 
day of misoprostol administration if they would rather have been at the hospital or if 
they were more content with being at home. Answer alternatives were yes/no. In Paper 
III, women who came back for clinical follow-up were presented with the questions; I. 
Are you satisfied with the method? II. Would you choose the method again? III. 
Would you recommend the method to others? They could respond by answering yes, 
no, or unsure. 
 
3.3 Data analysis 
3.3.1 Abortion Registry 
Data from the Abortion Registry was analysed using Statistical Package for the Social 
Sciences (SPSS), version 21 and R. The study population comprising 223,692 
terminations up to 12 weeks gestation was subdivided in three ways to compare 
characteristics. First it was divided according to the abortion method being medical or 
surgical. Second, this group was subdivided into two time periods 1998–2007 and 
2008–2013. These two time periods were chosen on the basis of surgical abortion 
being the dominant form of abortion prior to 2008 and medical abortion the most 
frequent form after 2008. This subdivision revealed no statistically significant 
differences in the characteristics of the study population between the two time periods 
and was not included in the study. Third, the population was divided according to 
abortion status, into women with no previous abortions and women with one or more 
previous abortions. Only data on women terminating a pregnancy up to 12 weeks 
gestation were included in the study.  
Comparisons were made using frequencies, univariate and multivariate logistic 
regression analyses and presented as odds ratios (OR). All were adjusted for the 
woman’s age and gestational age. 
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3.3.2 Hospital surveys 
The data was recorded and analysed using SPSS version 18. We used frequencies and 
percentages to present the results. Figures were made using Excel.  
 
3.3.3 The clinical cohorts 
To establish the databases and analyse data we used SPSS version 15 to 18. 
Frequencies, median, range and percentages were calculated to summarize results. 
Median and range instead of mean was chosen because most data, like age of the 
woman, gestational age, parity, induction-to-abortion interval, for instance, were not 
evenly distributed. Tools used for constructing figures were Excel and SPSS. 
Logistic regression analyses were made to establish statistical significance and 
associations between given variables and were presented as odds ratios (OR). 
Bivariate logistic regression analyses were used to determine association between 
gestational age and bleeding (Paper II), gestational age and induction-to-abortion 
interval (Paper III). To investigate the association between gestational age and pain 
adjusted for parity (Paper II), pain and parity adjusted for gestational age (Paper III), 
we used multivariate logistic regression analyses. 
 
3.2 Ethical considerations 
The studies performed have all the necessary approvals from the Committee for Medical 
and Health Research Ethics, Western Norway (number 2009/738). The use of data from 
the Abortion Registry included in Paper I has been permitted separately by the 
Norwegian Social Science Data Services (number 34010). 
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4. Summary of results 
4.1 Paper I: Implementing medical abortion with 
mifepristone and misoprostol in Norway 1998–2013 
After introducing medical abortion in 1998, a continuous increase in the percentage of 
all abortions performed medically was observed and found to be 5.9% in 1998 and 
82.1% in 2013. To evaluate the uptake of medical abortion and the different treatment 
modalities at hospital level, two hospital surveys were conducted. They revealed a 
rapid increase from none of the hospitals offering medical abortion in 1997 to 50% in 
2001 and 100% in 2010. Home administration of misoprostol was first introduced in 
2003 and after nine years, in 2012 92.1% of all hospitals offered the treatment 
modality. A rapid uptake of late first trimester abortion was also found from the first 
treatment in 2005 to being available at 84.4% of all hospitals in 2012. Most hospitals 
followed national and international guidelines with a treatment protocol consisting of 
200 mg mifepristone (94.7%), vaginal administration of misoprostol (94.2%) and UPT 
as follow-up (50%) in 2012.  
To evaluate the effect of an almost complete change in abortion methods, data from 
the Abortion Registry was analysed in more detail. Our study revealed that abortions 
are carried out increasingly earlier in the pregnancy. More abortions were conducted 
before seven weeks gestation (adjusted OR 2.33; 95% CI 2.29–2.38) among women 
performing a medical than a surgical termination and the percentage of abortions 
performed within nine weeks increased from 44.0% in 1998 to 77.8% in 2013. Women 
with repeat abortions on the other hand, had a higher preference for surgical abortion 
and performed their abortions later in pregnancy. After the introduction of medical 
abortion protocols, waiting time has been reduced from 11.3 days in 1998 to 7.3 in 
2013 for women requesting an abortion. Characteristics of women who performed a 
medical abortion or surgical abortion were relatively similar, except in the case of 
educational attainment where women opting for medical abortion had a slightly higher 
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educational level and women with repeat abortions had a poorer work force 
attachment and low educational level.  
 
4.2 Paper II: Medical abortion with home administration of 
misoprostol up to 63 days gestation  
We introduced home administration of misoprostol with no travel limits to simplify 
the abortion protocol for women in May 2006. It became the preferred method of 
abortion during the study period of three years, and 1,018 women choosing this 
treatment alternative were included. An efficacy rate of 93.6% complete abortions and 
an evacuation rate of 4.9% demonstrate results similar to other studies (12). On the 
other hand, we found that women with a gestational age of 56–63 days had higher 
odds for the need of surgical evacuation (OR 2.06; 95% CI 1.08–3.92). Prolonged 
bleeding was the most common reason for surgical evacuation. Only two women were 
in need of medical attention within the first 24 hours after administration of 
misoprostol. Bleeding increased with gestational age, but level of pain was 
independent from gestational age, but dependent on parity. Acceptability was high 
with 95.8% of all women being content with home administration of misoprostol. 
Only 7.1% of our study population lived further than one hour travel away. None of 
the treatment variables were influenced by travel distance. 
 
4.3 Paper III: Medical abortion at 63 to 90 days gestation 
After requests from women with a gestation over 63 days and who sought medical 
abortion we decided to introduce late first trimester abortions in 2005 inspired by 
previously published studies (13, 91). Two hundred and four women, approximately 
55% of all women requesting abortion in late first trimester, volunteered to have a 
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medical abortion and were included in the study. With an overall complete abortion 
rate of 91.7%, a median of two misoprostol applications needed and a median 
induction-to-abortion interval of 4.5 hours and 93.9 % of all abortions completed 
within eight hours, our findings were in line with previous studies (13, 101). We found 
no statistically significant differences in induction-to-abortion interval or number of 
misoprostol doses needed between the different gestational ages. After four weeks s-
hCG had been reduced by more than 97.3%. Women found the method highly 
acceptable, judging by our findings where 91.0% women (95% CI 87.5–94.5%) were 
content with the method, 76.1% (95% CI 70.9–81.4%) would choose the method if 
they needed an abortion again, and 81.9% (95% CI 77.2–86.6%) would recommend 




5.1 Methodological considerations 
All studies have strengths and limitations. The purpose of this section is to discuss 
how the chosen methodology influences the results generated, the conclusions drawn 
and the consequences they may have for the obtained results. 
 
5.1.1. Study design 
In Paper I we used two different study designs. Firstly a quantitative, questionnaire-
based survey to all hospitals performing abortion was used to investigate the 
prevalence of different treatment protocols and the implementation time of three 
treatment options, at hospital level. The surveys were conducted at two separate times 
in 2008 and 2012. We sought to examine a possible change in treatment trends before 
and after presenting the results of the first survey at the annual meeting of NSOG in 
2008, and the publication of updated national guidelines in 2009 (68). Secondly we did 
a registry-based study with data from the Abortion Registry, which is a compulsory 
population-based registry where the women are de-identified. The study does not 
qualify as a historical cohort study (107), because data are de-identified, preventing us 
from following each woman separately. Rather than a cohort of women, it consists of a 
cohort of terminations of pregnancies up to 12 weeks gestation in a study period of 15 
years. Women with repeat abortions within the study period are registered more than 
once, and their characteristics will be repeated and accumulated in comparison to 
women who only have one abortion. Neither does it qualify as a cross-sectional study 
(107), on the same basis that some women might occur several times in the dataset, 
and due to the data spanning a relatively long period of time. In our study we 
compared the characteristics of women who were exposed to medical abortion with 
women undergoing surgical abortion, and women with no previous abortion to women 
with repeat abortions. 
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Paper II and III are observational, prospective cohort studies (108), following women 
exposed to either home administration of misoprostol or medical abortion at 63 to 90 
days gestation. This design was chosen because we wanted to evaluate the efficacy 
and acceptability of the treatment for women at our hospital. The treatment protocols 
were not experimental. Randomised trials are the golden standard because estimates of 
the treatment effects would be more statistically valid and reliable (107). We have not 
been able to identify any studies randomising home administration of misoprostol with 
hospital-based treatment. Ashok et al. have conducted the two only randomised trials 
comparing surgical and medical late first trimester abortions (see paragraph 1.9) 
(96,100). Our aim was to implement two treatment methods with as little delay as 
possible, and not to compare them with other existing treatment options. For that 
reason we did not choose to do a randomised trial.  
The protocol for home administration of misoprostol was based on the already 
established procedure for women undergoing medical abortion up to 63 days in our 
clinic. A phone interview was chosen as the alternative contact with health personnel 
on the day of the actual abortion. Women were given the option of home 
administration of misoprostol regardless of travel time from the hospital. To evaluate 
the possible negative consequences for women living further than one hour from 
hospital, women were stratified between living closer or further away than one hour 
travel period (Paper II). For medical abortion at 63 to 90 days gestation, the protocol 
was based on internationally published studies (13, 91). The approach used for the 
latter was the same as when medical abortion was first introduced in 1998 (28).  
 
5.1.2 Precision 
The precision of a study is related to the extent of random errors. One way of assuring 
high precision is to increase the study sample size (107).  
The number of hospitals, which received the survey, was 40/38. Although the absolute 
numbers are small, the response rate was 100%. As this includes the complete number 
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of hospitals providing abortions, the absolute numbers of participants could not have 
been increased (Paper I).  
Since the Abortion Registry consists of an enormous amount of data, the precision was 
high. We chose to include women terminating their pregnancy up to 12 weeks 
gestation, and only 311 women lacking information on method and 358 women with 
extreme data were excluded from the analyses. The percentage of missing data was 
above 50% in the case of educational attainment, due to information on education not 
being included before year 2006, and not due to a random distribution of missing. As a 
result, data for almost 75% of women with a surgical abortion lacked information on 
educational level (Paper I).  
We did not make calculations on sample size (Paper II and III) because these studies 
were observational cohort studies aiming at evaluating the implementation of new 
procedures. In retrospect, we acknowledge that to be able to evaluate the effect of 
travel distance this would have been favourable (see also paragraph 5.1.1). The 
number of women living more than one hour from hospital in the cohort examined was 
too small to see any statistically significant differences between them and women 
living closer, even though the total number of participants in the study exceeded 1,000 
women (Paper II).  
 
5.1.3 Validity 
Hospital surveys: Selection bias (107) is unlikely in the hospital surveys, since we 
included all hospitals and there was a 100% response rate. Quality of the data was 
dependent on the responder at the actual hospital. Some discrepancies were found in 
the time specified as the first introduction of medical abortion in the questionnaires for 
2008 and 2012 for some of the departments (see paragraph 3.1.1). Historical data will 
always be subject to recall bias. The number of hospitals providing each treatment 
option and the treatment protocols in 2008 and 2012 are on the other hand believed not 
 48
to be subject to bias, because these treatments were in use at the time of reporting them 
through the questionnaire.  
Abortion Registry: Since the registry is compulsory, data are not subject to selection 
bias. The registry has never been compared and quality controlled against hospital data 
or other registries, and due to data being de-identified, this would not be possible. Data 
on parity, previous abortions, education, workforce attachment and marital status in 
the registry are based on women’s self-report. Stigma surrounding for instance social 
welfare and abortion might influence what women are willing to report. The number 
of previous abortions might for that reason be underreported. The quality of data in the 
registry is therefore unknown. On the other hand the amount of missing data is low, 
except in the case of education. The number of women with extreme measures who 
were excluded from the material were 358/223,692. 
We adjusted for gestational age because medical abortion is more prevalent before 
nine weeks gestation. Younger women might not have reached their maximum 
possible educational level, parity, and total number of abortions, or might not have 
entered the work force, so we also adjusted for the woman’s age. Parameters that were 
adjusted for gestational age and the woman’s age are: age, gestational age, parity, level 
of education, occupational status, marital status, previous abortions and method. 
Cohort studies: The percentage of women lost to follow-up was 4.7% (Paper II) and 
6.7% (Paper III). Measures of acceptability in Paper II were based on two questions 
where the only response alternatives were yes and no. The alternatives gave no room 
for options between yes and no, for example expressing a possible indifference, and 
we might have over rated the acceptability. The rapid increase in popularity of the 
method during the study period was hence seen as supporting our conclusion that the 
treatment was acceptable. A more fruitful approach could have been to ask about 





Data in Paper I came from a national compulsory register and hospital surveys to all 
hospitals performing abortion, with a 100% response rate, and are therefore 
generalizable for Norway. We belive the the findings to be transferable to other 
countries where abortion is covered by the National Health Services (NHS), and 
medical abortion is included among the treatment options available, as for instance 
other Scandinavian countries and the UK. The population data presented in Paper I  
reveals trends in line with data from Scandinavia (110) and Scotland (111) in regards 
to an increased use of medical abortion and concomitant shift of abortions being 
performed earlier in pregnancy. This trend, as well as the reduction in waiting time, is 
believed to be applicable to any country or region where access to medical abortion is 
increasing (Paper I). The rates of efficacy and acceptability found in the cohort studies 
are comparable with similar studies (12, 13, 87, 101, 103). High degree of 
reproducibility of results among studies strengthens  the recommendation of these 
treatment options. 
 
5.2 Major findings 
5.2.1 Transition from surgical to medical abortion 
After medical abortion was introduced in 1998 there has been an almost complete 
transition from surgical to medical abortion in Norway. This is similar to what is 
observed in the other Scandinavian countries (110) and in Scotland (111). After 
Portugal implemented their new law on abortion on request up to 10 weeks gestation 
in 2007, they chose medical abortion as their preferred abortion method in the public 
health system (112). Surgical abortions are performed in private clinics covered by the 
public health system and constituted 29.2% of all abortions in 2008 (112). The same 
trends in uptake of medical abortion are not necessarily seen in other countries, though 
it has been available for the same periods of time. Through a literature search using the 
words medical abortion, mifepristone, misoprostol, surgical abortion, trends and 
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implementation, 4 studies from France (113), the Netherlands (114), USA (10) and 
Vietnam (115) were identified and they reported the rate of all abortions performed 
medically. None of the studies presented figures more recent than 2011. Even though 
France together with China (21) has the longest history of providing medical abortion, 
the uptake has been slow. The slow increase in the use of medical abortion in France 
has partly been attributed to three factors: 1. strong regulations, 2. a minimal amount 
of research on medical abortion has been performed in France, and 3. medical abortion 
has primarily been available through public health services, and not the private 
services where most abortions are performed (113). In 2004 general practitioners were 
given the opportunity to provide medical abortion in France (116) and in 2007 49% of 
all abortions and 80% of all abortions under 63 days gestation were performed 
medically (113). The study from the Netherlands with data from 2005, presents an 
almost arbitrary distribution of methods and protocols, where 33.7% of the facilities 
use mifepristone and/or misoprostol for early termination of pregnancy (TOP), and 
45.7% of the providers used either mifepristone or misoprostol as a single agent (114). 
After the registration of mifepristone in the USA in 2000, there was at first a rapid 
increase that later slowed down. Estimates for 2008 were that about 24% of med-
eligible abortions were performed medically (10). In Vietnam, mifepristone was first 
introduced in 1992, and in 2011 23.1% of all abortions were performed medically 
(115). Except for in Scandinavia and Scotland, medical abortion does not seem to have 
replaced surgical abortion to a large extent (Figure 6). 
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Figure 6.  Percentage of all abortions performed medically (France (113), USA 
(10), Vietnam (115), Portugal (112), Scotland (111), Sweden (110), 
Denmark (110), Sweden (110), Norway (33)) 
 
In comparison to France, where the process of implementing medical abortion seems 
to have been top-down, instrumented by the Government and health authorities, the 
process in the USA and Norway has rather been bottom-up, driven by research and 
women’s health advocates (113). In Norway, gynaecologists and the Norwegian 
Society of Obstetrics and Gynaecology (NSOG) have been a leading force in 
introducing medical abortion and promoting new treatment options (see paragraph 
1.2). There has also been a task shift in work load from mainly physicians to nurses. 
At the same time, a transfer of almost all abortions out of the operation theatres and 
over to the out patient clinics releases capacity to other patient groups.  
When resources are low, the health services have to make priorities (117). In a global 





























Studies show that task shifting might be an essential way to improve access to health 
services where there is a shortage of health personnel and poor resources (11, 118). 
Experiences from Norway could therefore also be beneficial for women’s reproductive 
health on a global scale. 
In Norway, TOPs were originally conducted by the junior trainees in Obstetrics and 
Gynaecology who would rapidly learn how to do a vacuum aspiration. In recent years, 
surgical abortion has been replaced by medical abortion (Paper I). Misoprostol instead 
of surgery is also exceedingly used as treatment for incomplete abortions (72, 119) and 
miscarriages (120). In a study from Finland, conducted at a time when the distribution 
between surgical and medical abortions was approximately 50–50%, medical abortion 
had slightly more adverse events than surgical abortion. This was mainly attributed to 
haemorrhage and incomplete abortions, while the majority with injuries were in the 
surgical group (121). Little is still known about the effect on surgical evacuation skills 
when medical procedures almost replace surgery completely. 
 
5.2.2 Access 
Waiting time and mandatory counselling is claimed to affect women’s access to 
abortion in many countries (46, 47). In an overview from the USA it was found not to 
affect the women’s decision but to influence personal and economic cost, and to result 
in a delay responsible for an increased number of second trimester abortions (47). In 
the Netherlands, on the other hand, where they have both mandatory counselling and 
five days waiting time 95%, of all abortions are performed within the 12 first 
gestational weeks (46). This could still influence women’s access to medical abortion, 
since many medical abortion protocols have an upper limit of 63 days, or in some 
places, as for instance France, a legal upper limit of 49 days for abortions in private 
practice (116). In France the law requires one week obligatory waiting time between 
the request for an abortion and termination. At the same time, many women wait about 
a week before they get an appointment with an abortion provider (113). By the time 
they are ready to terminate the pregnancy many women would have passed the upper 
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limit for a medical abortion. Norway has no mandatory waiting time, but the mean 
number of days between a request for abortion and termination was still 11.3 days in 
1998. After the introduction of medical abortion the mean number of waiting days was 
reduced to 7.3 in 2013, and the reduction was mainly for women undertaking a 
medical abortion (Figure 7). In Figure 7, one can see an abrupt drop in waiting days 
for women opting for medical abortion, from approximately 12 to 8 days within the 
first years. After the introduction of home administration of misoprostol and most 
probably a single visit approach, a further reduction to 6.3 days is observed (Figure 7).  
This reduction has improved access to early medical abortion, and can also in part 
have contributed to the successful implementation of the procedure. 
 
 
Figure 7.  The mean number of waiting days between a registered request at the 
hospital and termination 
 
 
5.2.3 Introducing new procedures 
According to the hospital surveys Norwegian gynaecologists seem to be loyal to 
national guidelines and are eager to introduce new treatment options (Paper I). Results 
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from the 2008 survey were presented at the annual meeting of NSOG in September 
2008. In the following months, Haukeland University Hospital, as a leading centre of 
expertise on medical abortion in Norway, received numerous contacts from 
gynaecologists and nurses from other hospitals requesting treatment protocols and 
information about home administration of misoprostol and late first trimester 
abortions. As a result of the numerous requests for treatment protocols from other 
hospitals, a new survey was conducted in 2012. This survey revealed a rapid increase 
in the uptake of home administration of misoprostol and late first trimester abortions 
after year 2008 (Paper I). 
Experience with the treatment has accumulated over the years. Introduction of new 
and simplified treatment procedures was facilitated through a close cooperation with 
nurses. Medical abortion was seen as progress for women and a possibility of gaining 
new knowledge and medical responsibility among the nursing staff. This positive 
attitude has been one of the driving forces promoting a task shift in treatment 
responsibility and workload from gynaecologists to nurses. Increasingly nurses are 
also trained in operating ultrasound, simplifying the abortion process further and 
allowing women to complete their treatment with only one health professional, similar 
to what is seen in Sweden (122). 
Home administration of misoprostol: When home administration of misoprostol up to 
63 days gestation was introduced at Haukeland University Hospital in 2006, the only 
other options for home administration of misoprostol in Norway were up to 56 days in 
Førde Hospital (treatment protocol written by Mette Løkeland) and up to 49 days at 
Ullevål University Hospital (29). Numerous studies enforced a travel restriction of 
most commonly one hour on women requesting home administration of misoprostol 
(87, 123, 124). No studies with travel limits addressed the necessity of proximity to the 
provider. And at the same time, home administration up to 63 days was commonly in 
use in the USA without a mention of travel limitations (85). In our study (Paper II) no 
travel restrictions were made. Unfortunately it turned out that only 7.1% of our total 
study population comprising 1,018 women lived further than one hour away. For that 
reason, data comparing women living closer or further away than one hour were not 
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statistically significant. On the other hand, we found that only two women were in 
need of medical assistance on the day of misoprostol administration. These women are 
the only two women that would have been treated for complications before going 
home if they had performed medical abortion as day patients in hospital. Most surgical 
evacuations were done due to prolonged bleeding, at a time when these women would 
have left hospital if the termination had taken place there rather than at home. These 
findings supported travel limitations as not medically necessary at these gestational 
ages, even though the cohort was too small to compare women living further or closer 
than one hour from hospital (see paragraph 5.1.1) (Paper II). The number of women 
choosing this treatment option increased during the study period (Figure 8). As 








The risk of needing a surgical evacuation was increased for women with a gestational 
age of 56–63 days. This is in line with other studies (71) and supports the addition of 
400 mcg misoprostol after four hours in cases of no expulsion to the treatment 
protocol for gestational ages above 56 days (67, 73). 
Late first trimester abortions: Women were increasingly querying about medical 
abortion for late first trimester gestations. Previous experiences with second trimester 
medical abortions and the implementation of medical abortion in 1998 ensured 
confidence and a positive attitude towards implementing a new treatment option in our 
team. Approximately 55% of women eligible for medical treatment chose this option 
during the study period (Paper III). Slightly higher rates of surgical abortions in 
comparison to early medical abortion are however maintained at this gestational age 
(Paper I). We like to think of the survey and presentation at the annual meeting of 
NSOG in 2008 as a form of intervention resulting in a rapid increase in access to late 
first trimester abortions at Norwegian hospitals.  
The complete abortion rate (91.7%) in our study was slightly lower in the first 254 
women who received the treatment than in other studies (13). When revising our data 
for a further 705 women, the complete abortion rate had increased to 94.6%. There is 
considerable indirect evidence that there is a learning curve after the introduction of 
medical abortion (1). In a French study, physicians who performed the higher numbers 
of medical abortions per year had a higher rate of complete abortions than those who 
only conducted a few (116).  
There was a reduction in s-hCG of more than 97.3% after four weeks, and we 
concluded that s-hCG can be used for follow-up also at this gestational age, in addition 
to observation of expulsed pregnancy products at termination. As a single agent for 
follow-up it is less applicable, since late first trimester abortions are performed close 
to the 12 weeks legal limit in Norway. Through the inspection of expulsed pregnancy 
products, all ongoing pregnancies were detected in our study and s-hCG was used as 




There has been put much emphasis in research on doses, intervals between and 
administration of mifepristone and misoprostol to reduce side effects and increase 
acceptability (see paragraph 1.5 and 1.6). Surprisingly little research is done on pain in 
relation to treatment (125). Level of pain is always a subjective experience and it is 
partly a psychological and a physiological response (126, 127). Studies on surgical 
abortion have found psychological factors like pre-abortion depression and 
ambivalence about the abortion decision, nulliparity, and menstrual pain to increase 
the level of pain experienced (127). In our studies nulliparous women experienced 
higher levels of pain than parous women (Paper II and III), and the need for opiates 
decreased with increasing parity (Paper III). Research has found that nulliparity, 
higher gestational age and menstrual pain also increase the risk of pain in medical 
abortion (72, 128, 129). When we adjusted for parity in our study, no association 
between pain and gestational age was found (Paper II and III). Other studies confirm 
no relationship between pain and gestational age (130). There is no reason to believe 
that psychological effects like depression and ambivalence should have a different 
impact on pain during a medical abortion (126). Several participants commented, in 
the follow-up consultations, that the abortion provider had underestimated the level of 
pain, and this made them uneasy (Paper III). Studies have identified that acceptability 
was reduced among women who experienced more pain and bleeding than they 
expected (129).  
In our studies women were given prophylactic analgesics in the form of diclofenac, 
paracetamol and kodeinsulphate (Paper II and III). In a German study of terminations 
up to 49 days gestation, only 22% required light analgesia (131), and a study 
randomising prophylactic and therapeutic ibuprofen for a medical abortion up to 63 
days gestation found no differences in pain score between the groups (132). Kopp 
Kalner et al. found no association between the need for extra analgesics and 
acceptability (130). Much has yet to be investigated to find individual and optimal 
protocols for pain management. 
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Pursuing a different line of acceptability, an Italian study found that women 
undergoing a medical abortion resumed intercourse faster and had a higher sexual 
function after the abortion than women opting for surgical abortion (133). This could 
be related to a higher anxiety level and ambivalence towards the abortion seen among 
women opting for surgical abortion in comparison to medical abortion in some studies, 
rather than being a result of the method as such (131, 133). Though acceptability 
levels are generally high among women undergoing medical abortion, more can still 
be done to maximize acceptability and identify factors that improve acceptability. This 
is particularly important when medical abortion is replacing surgical abortion and the 
focus on individual choice of procedure is less prominent. 
 
5.2.5 Choice 
As argued in paragraph 1.4, choice is a complex issue that has to take into account 
both inner preferences and ambiguities and external values and recommendations. 
Choice is therefore very often irrational (52). At Haukeland University Hospital 
medical abortion was made the method of choice for early first trimester abortions in 
2006 and late first trimester in 2007. These decisions are also made at other hospitals 
in Norway (58). Women who actively requested surgical abortion were given that as 
an option. As mentioned in paragraph 1.4 most procedural changes in medicine are 
based on evaluation and medical choice by the health service after a process of gaining 
experience and knowledge about the innovative treatments. The Norwegian Health 
Minister supports this choice on the hospital level, and believes that it is not contrary 
to patient rights of autonomy according to the law on patient rights (58). NSOG’s 
educational committee has discussed the problems of maintaining skills in laparotomy 
when laparoscopy is replacing open surgery, a problem that could be transferred to 
vacuum aspirations. They have concluded that it is unethical to perform a laparotomy 
for the purpose of maintaining skills, and we have to find other ways of securing 
women’s treatments. 
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 In a study from Germany at a time when only 6% of all abortions were performed 
medically 52% of the women choosing surgical abortion stated that they chose surgery 
because it was a widely used and well known procedure (131). In the same study the 
decision on abortion method was highly influenced by advice from health personnel in 
32.9% of the cases, mainly recommending surgical abortion (131). This coincides with 
initial experiences at Haukeland University Hospital when most women had little 
knowledge of medical abortion and relied on recommendations from their GP. Today 
when medical abortion is the most frequently used method this has changed in favour 
of medical abortion.  
In the German study, women who chose surgical abortion were more ambivalent and 
had higher anxiety scores than those who chose medical abortion and 50% chose 
surgical abortion because they wanted to be unaware of the treatment (131). Making 
the choice of having an abortion can be an ambivalent and stressful task (131, 134). To 
some women making that choice is stressful enough, and they don’t want to have to 
make yet another decision on method (134); while for others the choice it self is 
important (54). Medical abortion has increased women’s participation. In many ways 
it has relieved the physician of the “burden” of being the active instrument in an 
abortion. Instead women actively ingest mifepristone and administer misoprostol 
themselves. Psychologically that is a wanted development for many women, but not 
for all (54).  
Although making a choice on method based on medical preference on the hospital 
level is in line with what is happening in almost any field of medicine and is not seen 
as violating patient autonomy (58), we have to recognize the extraordinary position of 
abortion within the medical field. Abortion is, as mentioned, probably the most 
politicized treatment in medicine, surrounded with a variety of stigma and morals (1) 
and we should for that reason maybe be extra careful in respecting individual 
preferences of women. Unfortunately the violation of some women’s preferences for 
surgical abortion has probably been the consequence of an almost complete transition 
from surgical to medical abortion. 
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6. Conclusions 
We found an almost complete transition in treatment for unwanted pregnancies from 
surgical to medical abortion. There has been a relatively fast increase in the percentage 
of hospitals offering medical abortion to women after 1998, and a rapid increase in the 
provision of home administration of misoprostol and late 1.trimester abortions after 
2008. Results from the surveys revealed that Norwegian hospitals offer a diversity of 
treatment protocols anchored in national and international guidelines.  
Medical abortion requires fewer resources and the implementation of medical 
abortion, has given the hospitals a possibility to reallocate services for other patient 
groups without compromising access to abortion for women. 
After the introduction of medical abortion the mean waiting time between a request for 
an abortion until termination dropped from 11.3 to 7.3 days and women perform their 
abortions earlier in pregnancy. Women with repeat abortions have higher odds for 
performing a surgical abortion and both women who opt for a surgical abortion and 
women with repeat abortions have a lower educational attainment, and perform their 
abortions later in the first trimester. It is not clear if the tendency to perform a surgical 
abortion for this group is related to a low acceptability of medical abortion as a 
method, or rather attributed to higher gestational age (Paper I). 
Home administration became the most frequently used method for termination up to 
63 days gestation at Haukeland University Hospital. Efficacy and acceptability of the 
treatment was high and in line with other studies (12). Women were given the option 
of home administration of misoprostol without limits to travel time between their 
home and the hospital. The study did not reveal any medical reasons to enforce travel 
restrictions of one hour for women who prefer home administration of misoprostol 
(Paper II). Access to home administration of misoprostol increased from 23.7% of all 
hospitals offering the treatment in 2008 to 92.1% in 2012 (Paper I). 
Medical abortion at 63–90 days gestation was found to be highly acceptable with a 
rate of complete abortions of 91.7% that is similar to other studies (see paragraph 1.9). 
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Median induction-to-abortion time was 4.5 hours and 93.7% had a complete abortion 
within 8 hours. S-hCG dropped more than 97.5% in four weeks, and can together with 
an inspection of the pregnancy products, be used to confirm the termination (Paper 
III). The prevalence of hospitals offering this method increased from 23.7% in 2008 to 




7. Implications and future research 
The implications of implementing medical abortion have been an almost complete 
change in the abortion treatment. Norwegian gynaecologists seem to be informed 
about medical research, and acquire and implement early advances in treatment 
options, and follow protocols. With simplified procedures for termination of 
pregnancy, there has been a task shift in the treatment of women with unwanted 
pregnancies from physicians to nurses. Cost benefit has been substantially increased 
and release of medical and surgical capacity should have improved access for other 
patient groups without violating the access to abortion for women with unwanted 
pregnancies. Access to surgical abortion might have been reduced at the cost of 
women’s choice of method. At the same time women have gained a more personalized 
treatment. 
Future research 
1. With vanishing numbers of evacuations being performed in early pregnancy 
both for termination of pregnancy and miscarriages, we need to evaluate and 
secure the quality of our surgical procedures. 
2. Acceptability of medical abortion among women is high, but little is known 
about which factors are important in making the treatment more acceptable. 
Many important studies on the route of administration of misoprostol and 
dosages have been performed to reduce side effects. Pain management and 
modulation on the other hand have not been as thoroughly investigated.   
3. Expansion of home administration of misoprostol beyond nine weeks gestation. 
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Utfører de medikamentell abort (set ring)? JA /Nei   Når vart det innført (mnd/år):…… 
 
 
For kva gestasjonslengder har de tilbod om medikamentell abort (set ring og mnd/år innført)? 
 
< 9 veker ………… 9-12 veker: ………… > 12 veker: ………….. 
 
 
Har de tilbod om medikamentell abort heime? JA /Nei Frå når (mnd/dato): …….. 
 
 
For kva for gestasjonslendge har de tilbod om medikamentell abort heime (set ring)? 
 
< 7 veker <8 veker < 9 veker > 9 veker (angi lengde)…….. 
 
 
Kva for type kontroll nyttar de etter abort <9 veker  (set ring)? 
 
Klinisk/UL s-hCG  u-hCG  ingen 
 
 
Kva for type kontroll nyttar de etter abort 9-12 veker  (set ring)? 
 
Klinisk/UL s-hCG  u-hCG  ingen 
 
 
Kva for dose mifepriston nyttar de (set ring)? 
 
200 mcg 400 mcg 600 mcg 
 
 
Gjev de misoprostol (set ring):   vaginalt/per oralt 
 
 
Om lag kor mange abortar har de i året (2011)?………………. 
 
Om lag kor mange er medikamentelle (2011)? …………………. 
 
 









Namn på den som utfyller skjemaet:……………………………………………………………….. 
 
TAKK FOR HJELPA      Returadresse:  Mette Løkeland 
          Kvinneklinikken 
          Jonas Liesv  
          5021 BERGEN 




List of hospitals: 
 
1. Akershus University Hospital, Lørenskog 
2. Blefjell Hospital, Notodden (Only 2008) 
3. Førde Hospital, Førde 
4. Helgeland Hospital, Sandnessjøen 
5. Hammerfest Hospital, Hammerfest 
6. Kirkenes Hospital, Kirkenes 
7. Stord Hospital, Stord 
8. Haugesund Hospital, Haugesund 
9. Stavanger University Hospital, Stavanger 
10. Ålesund Hospital, Ålesund 
11. Volda Hospital, Volda 
12. Kristiansund Hospital, Kristiansund 
13. Molde Hospital, Molde 
14. Nordfjord Hospital, Nordfjordeid 
15. Bodø Hospital, Bodø 
16. Lofoten Hospital, Gravdal 
17. Oslo University Hospital (Rikshospitalet), Oslo (Only 2008 
18. Ringerike Hospital, Hønefoss 
19. St. Olav Hospital, Trondheim 
20. St. Olav Hospital/Orkdal Hospital, Orkanger 
21. Bærum Hospital, Gjettum 
22. Drammen Hospital, Drammen 
23. Tønsberg Hospital, Tønsberg 
24. Gjøvik Hospital, Gjøvik 
25. Lillehammer Hospital, Lillehammer 
26. Kongsvinger Hospital, Kongsvinger 
27. Elverum Hospital, Elverum 
28. Levanger Hospital, Levanger 
29. Namsos Hospital, Namsos 
30. Telemark Hospital, Skien 
31. Østfold Hospital, Fredrikstad 
32. Sørlandet Hospital Arendal, Arendal 
33. Sørlandet Hospital Kristiansand, Kristiansand 
34. Oslo University Hospital (Ullevål), Oslo 
35. Tromsø University Hospital, Tromsø 
36. Harstad Hospital, Harstad  
37. Narvik Hospital, Narvik 
38. Vesterålen Hospital, Stokmarknes 
39. Voss Hospital, Voss 
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Begjæringen innvilget iht. § 2.3 (sett ev. flere kryss)
Begrunnelse for avslag i primærnemnd. Bruk eget ark.
Spesifiser
avslått
Bruk eget ark for nemndens begrunnelse.
Enstemmig avslag Ja Nei Begrunnelse for dissens. Bruk eget ark.
Begjæring oversendt fylkesmannen for
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